卡西瑞维单抗/英地维单抗与瑞德西韦联合治疗B细胞耗竭患者的持续性SARS-CoV-2感染
Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients.
作者信息
Dioverti M Veronica, Gaston David C, Morris C Paul, Huff Carol Ann, Jain Tania, Jones Richard, Anders Viki, Lederman Howard, Saunders Jacqueline, Mostafa Heba H, Avery Robin K
机构信息
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Division of Medical Microbiology, Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
出版信息
Open Forum Infect Dis. 2022 May 26;9(6):ofac064. doi: 10.1093/ofid/ofac064. eCollection 2022 Jun.
Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome coronavirus 2 infections with evidence of active viral replication, due to inability to mount an adequate humoral response to clear the virus. We present 3 B-cell-depleted patients with prolonged coronavirus disease 2019 infection who were successfully treated with a combination of casirivimab/imdevimab and remdesivir.
由于无法产生足够的体液免疫反应来清除病毒，B细胞严重耗竭的患者可能会出现严重急性呼吸综合征冠状病毒2的长期感染并有病毒活跃复制的证据。我们报告了3例B细胞耗竭的2019冠状病毒病长期感染患者，他们接受了卡西瑞维单抗/伊德维单抗和瑞德西韦联合治疗并取得成功。
Zotero 插件